New hope for ALS patients: experimental drug shows promise in early trial

NCT ID NCT05508074

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 23 times

Summary

This study tested an experimental drug called IFB-088 added to the standard ALS medication riluzole in 51 people with bulbar-onset ALS (a form that first affects speech and swallowing). The goal was to see if the combination is safe and shows signs of slowing the disease. Participants took either IFB-088 plus riluzole or a placebo plus riluzole for 6 months, and researchers tracked their muscle function, breathing, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA

    Marseille, 13385, France

  • CHU Bretonneau

    Tours, 37044, France

  • CHU de Nantes - Hôpital Laennec

    Nantes, 44093, France

  • CHU de Toulouse - Hôpital Pierre-Paul Riquet

    Toulouse, 31059, France

  • Centro Clinico NeMO per le Malattie Neuromuscolari

    Gussago, 25064, Italy

  • Hôpital Neurologique Pierre Wertheimer

    Bron, 69677, France

  • IRCSS Istituto Neurologico Carlo Besta

    Milan, 20133, Italy

  • Ospedale Civile Sant'Agostino Estense

    Baggiovara, 41126, Italy

  • Sant'Andrea Hospital Unit of Neuromuscular Disorders

    Roma, 00189, Italy

Conditions

Explore the condition pages connected to this study.